10 completed, 2 recruiting, 2 withdrawn, 1 not yet recruiting. 2 Phase 2, 2 Phase 3, 2 Phase 4, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 4 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Intra-Abdominal Infections: new trials by email Literature Review of Intra-Abdominal Infections trials Research Report on Intra-Abdominal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gelaspan vs Crystalloid Therapy in Sepsis Balanced Gelatin Solution, Acetate Ringer's Solution - Sepsis, Intra-Abdominal Infections | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 318 | 2026-02-13 | 2026-03-20 |
| Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers JKN2501, Placebo - Bacterial Infections, Urinary Tract Infections | Phase 1 | Recruiting | Joincare Pharmaceutical Group Industry Co., Ltd | 66 | 2025-08-22 | 2025-10-03 |
| Capillary Leak Index as a Prognostic Indicator for Post-Operative Abdominal Sepsis in Critically Ill Patients Intra-Abdominal Infections, Intestinal Obstruction | Completed | Ain Shams University | 100 | 2025-03-04 | 2025-12-24 | |
| Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI Meropenem and Pralurbactam, Saline, Ceftazidime-avibactam - Intra-abdominal Infections | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 786 | 2024-10-31 | 2024-10-09 |
| Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED) IMX-BVN-4 and IMX-SEV-4 - Respiratory Tract Infections, Urinary Tract Infections | Withdrawn | Inflammatix | 2022-12-01 | 2023-12-27 | ||
| Gut Microbiota Analysis in IAI Patients With Sepsis-associated Liver Dysfunction Gut microbiota Analysis - Gut Microbiota, Intra-abdominal Infections | Completed | Chinese Medical Association | 20 | 2022-01-03 | 2022-11-28 | |
| Procalcitonin Guided Antibiotic Therapy Procalcitonin-guided antibiotic treatment, Standard of Care Antibiotic Treatment - Intra-Abdominal Infections | Not applicable | Withdrawn | Columbia University | 2021-09-01 | 2021-10-21 | |
| TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis TriVerity - Respiratory Tract Infections, Urinary Tract Infections | Completed | Inflammatix | 1441 | 2020-02-28 | 2024-10-22 | |
| LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI) LYS228, Standard of care therapy - Intra-abdominal Infections | Phase 2 | Terminated | Novartis Pharmaceuticals | 3 | 2018-05-15 | 2021-10-11 |
| Abdominal SepsiS Study: Epidemiology of Etiology and Outcome Intra-Abdominal Infections | Completed | European Society of Intensive Care Medicine | 2200 | 2016-01-01 | 2017-06-29 | |
| Tygacil Drug Use Investigation Tigecycline (Tygacil) - Intra-Abdominal Infections, Skin Disease, Infectious | Completed | Pfizer | 116 | 2013-04-15 | 2019-02-06 | |
| Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004) Relebactam 250 mg, Relebactam 125 mg, Imipenem/cilastatin - Intra-abdominal Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 351 | 2012-06-01 | 2019-06-10 |
| Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care: - Adenovirus, Anesthesia | Completed | Daniel Benjamin | 3520 | 2011-11-01 | 2023-09-06 | |
| A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection Metronidazole, Ceftriaxone sodium - Intra-abdominal Infections | Phase 3 | Completed | Pfizer | 38 | 2011-11-01 | 2014-01-24 |
| A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections Doripenem - Infection, Cross Infection | Phase 4 | Completed | Janssen-Cilag Ltd.,Thailand | 270 | 2009-06-01 | 2013-10-30 |
| Post-Authorization Study Evaluating Safety Of Tigecycline Tigecycline - Intra-Abdominal Infections, Skin Disease, Infectious | Completed | Pfizer | 115 | 2008-08-01 | 2012-02-01 |
Intraabdominal Infections (16) · Infections (6) · Sepsis (6) · Urinary Tract Infections (5) · Respiratory Tract Infections (3) · Soft Tissue Infections (3) · Bacterial Infections (2) · Encephalitis (2) · Skin Diseases, Infectious (2) · Adenoviridae Infections (1) · Anxiety Disorders (1) · Appendicitis (1) · Arrhythmias, Cardiac (1) · Autistic Disorder (1) · Bipolar Disorder (1)
Infections (10) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Systemic Inflammatory Response Syndrome (6) · Urogenital Diseases (6) · Inflammation (5) · Male Urogenital Diseases (5) · Respiratory Tract Diseases (5) · Urologic Diseases (5) · Bacterial Infections and Mycoses (3) · Brain Diseases (3) · Central Nervous System Diseases (3) · Nervous System Diseases (3)
Metronidazole (2) · Tigecycline (2) · Alfentanil (1) · Amikacin (1) · Aminocaproic Acid (1) · Bosentan (1) · Cefepime (1) · Ceftriaxone (1) · Cidofovir (1) · Cilastatin, Imipenem Drug Combination (1) · Ciprofloxacin (1) · Clozapine (1) · Doripenem (1) · Fosfomycin (1) · Haloperidol (1)
Pfizer (3) · Inflammatix (2) · Ain Shams University (1) · Chinese Medical Association (1) · Columbia University (1) · Daniel Benjamin (1) · European Society of Intensive Care Medicine (1) · Janssen-Cilag Ltd.,Thailand (1) · Joincare Pharmaceutical Group Industry Co., Ltd (1) · Merck Sharp & Dohme LLC (1) · Novartis Pharmaceuticals (1) · Qilu Pharmaceutical Co., Ltd. (1) · Shanghai Zhongshan Hospital (1)
China (4) · United States (3) · Belgium (1) · Canada (1) · Egypt (1) · Greece (1) · Israel (1) · Japan (1) · Singapore (1) · Thailand (1) · United Kingdom (1)
Ahmed M Ahmed, MD. (1) · Changhong Miao, MD (1) · Chi Hornik, PharmD (1) · Hanaa A El-Gendy, MD (1) · Katherine Fischkoff, MD (1) · Wenkui Yu, Ph.D. (1) · Yunfei Ju, MM (1)
PMID 11172350, PMID 23772042, PMID 23772045, PMID 23772047, PMID 24171518, PMID 24287460, PMID 24614374, PMID 24949994, PMID 25442806, PMID 25887649, PMID 26039810, PMID 26496306, PMID 26677396, PMID 26926644, PMID 27503659, PMID 27522443, PMID 28137820, PMID 28268067, PMID 28290120, PMID 28779462, PMID 29084742, PMID 29271816, PMID 29435949, PMID 29677389, PMID 30061293, PMID 30574564, PMID 30790601, PMID 31317556, PMID 31548185, PMID 31814149, PMID 32324313, PMID 32497307, PMID 33029806, PMID 33406974, PMID 33903114, PMID 34040329, PMID 34302290, PMID 35370711, PMID 35491971, PMID 36186801, PMID 38117435, PMID 38850687, PMID 41247430